Undifferentiated (Embryonal) Sarcoma
Back to Diseases List
Associated Genetic Biomarkers
NCI Definition: An aggressive malignant mesenchymal neoplasm that arises from the liver and usually occurs in older children. It is composed of immature spindle, stellate, polymorphous, and giant cells. 
There are 2 clinical trials for undifferentiated (embryonal) sarcoma, of which 2 are open and 0 are completed or closed. Of the trials that contain undifferentiated (embryonal) sarcoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
Deficient, MLH1, and MSH2 are the most frequent gene inclusion criteria for undifferentiated (embryonal) sarcoma clinical trials .
Doxorubicin, nivolumab, and ribociclib are the most common interventions in undifferentiated (embryonal) sarcoma clinical trials.
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.